Latest Issue
Get instant access to latest e-book

LATEST NEWSRead more...

23

Jan 2020

INHIBITOR Therapeutics Receives prostate cancer IND Clearance from FDA

INHIBITOR Therapeutics Inc a biopharmaceutical company focused on the discovery development and commercialization of innovative therapeutics to inhibit progression of cancerous and noncancerous proliferation disorders today announced that the company has received Investigational New Drug IND clearan...

23

Jan 2020

Genialis and Oncologie Collaborate on Precision Medicine Initiative in Gastric Cancer

Genialis a leader in applied data science for the development of precision medicines today announced a collaborative partnership with Oncologie an international clinicalstage biopharma developing nextgeneration immunotherapies for cancer Initial activities will focus on the use of Genialis Expressio...

22

Jan 2020

Hitachi Chemical Advanced Therapeutics Solutions and Ori Biotech Announce a Joint Development Agreement

Hitachi Chemical Advanced Therapeutics Solutions LLC HCATS a US subsidiary of Hitachi Chemical Co Ltd that engages in contract manufacturing and manufacturing development of cell therapy products and Ori Biotech Ltd Ori an innovator in cell and gene therapy CGT manufacturing today announced they hav...

22

Jan 2020

Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies

Ncardia and BlueRock Therapeutics today announced an agreement covering process development technologies for the manufacture of induced pluripotent stem cell iPSCderived cardiomyocytes Under the terms of the agreement Bluerock gains access to Ncardias largescale production processes and intellectual...

21

Jan 2020

Crescita Signs Exclusive Distribution Agreement with FILLMED

Crescita Therapeutics Inc a commercial dermatology company with manufacturing capabilities and a portfolio of nonprescription skincare products and prescription drug products for the treatment and care of skin conditions diseases and their symptoms today announced that it has entered into a distribu...

20

Jan 2020

Bridge Biotherapeutics Announces FDA IND Clearance for BBT-176, an EGFR TKI for NSCLC

Bridge Biotherapeutics Inc a clinical stage biotech company headquartered in Seongnam Republic of Korea announced that the Investigational New Drug IND application submitted to the US Food and Drug Administration FDA has been cleared on January th

18

Jan 2020

Mundipharma enters into partnership with Samsung Bioepis to expand Biosimilars to Hong Kong and Taiwan

Mundipharma today announced a partnership with Samsung Bioepis to commercialize the first biosimilar candidates from Samsung Bioepis in Taiwan and Hong KongThe partnership includes biosimilar candidates from Samsung Bioepis in the field of immunology and oncology including SB adalimumab SB etanercep...

press releasesRead more...

23

Jan 2020

Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy

Jazz Pharmaceuticals plc announced the submission of a New Drug Application NDA to the US Food and Drug Administration on January seeking marketing approval for JZP an investigational medicine for the treatment of cataplexy and excessive daytime sleepiness EDS in patients years of age and older...

23

Jan 2020

Aruvant Receives Orphan Drug Designation for ARU-1801 for the Treatment of Sickle Cell Disease

Aruvant a clinicalstage biopharmaceutical company focused on developing and commercializing transformative therapies for the treatment of severe blood disorders today announced that the US Food and Drug Administration has granted Orphan Drug designation to ARU Aruvants investigational therapy for th...

22

Jan 2020

Denovo Biopharma Enters into Option Agreement with Rumpus Therapeutics for Selected DB102 (Enzastaurin) Clinical Indications

Denovo Biopharma LLC a pioneer in applying precision medicine to develop innovative therapies today announced it has entered into an exclusive OptiontoLicense Agreement with Rumpus Therapeutics for selected indications for DB Rumpus Therapeutics gains the option to acquire an exclusive license to de...

22

Jan 2020

OBI Pharma Granted U.S. FDA Orphan Drug Designation for the Treatment of Gastric Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999

OBI Pharma Inc a Taiwan biopharma company TPEx today announced that the US Food and Drug Administration FDA has granted Orphan Drug Designation for OBI for the treatment of Gastric Cancer OBI is a firstinclass antibody drug conjugate targeting Globo H a glycolipid antigen On December OBI was gran...

21

Jan 2020

Discover the Latest Information and Seize Market Opportunities in the Annual Event of the CRO & CMO Industry

As the pharmaceutical market demands in China continue to grow Chinas pharmaceutical policies become gradually clear which provides broad space for the development of pharmaceutical enterprises The CRO CMO industry an important part of the RD industry chain of pharmaceutical enterprises has also us...

21

Jan 2020

FDF China to be held in June to boost Chinese pharmaceutical enterprises

FDF Chinacollocated with CPhI China will be held fromJune at Shanghai New International Expo Centre SNIEC More and more formulation enterprises need to implement strategic layout to step up cooperation in innovation and facilitate the integration of science and technology with economic growth and...

EventsRead more...

24 - 25

Jan 2020

27 - 30

Jan 2020

Arab Health 2020

Dubai World Trade Centre

28 - 30

Jan 2020

2nd Longevity Therapeutics 2020

Holiday Inn Golden Gateway Hotel

28 - 30

Jan 2020

29 - 30

Jan 2020

03 - 06

Feb 2020

Medlab Middle East 2020

Dubai World Trade Centre

04 - 05

Feb 2020

14th annual Parallel Trade conference

Holiday Inn London - Kensington Forum

05 - 07

Feb 2020

The Biologics Alliance 2020

ICRS - International Cartilage Regeneration & Joint Preservation Society
Carlsbad

Advertisements

TOP ARTICLES

KNOWLEDGE BANK

  • Interviews

    Merck

    Staff Engineer, Manufacturing Science and Technology, South East Asia

    Karen Chan is a process engineer at Merck Pte Ltd Chan has six years of experience in the biopharmaceutical industry and two years of experience in research development She provides technical support in areas such as process development troubleshoot...
  • Articles

    Treatment of Cancer Using Combined Chemo-Photo Approach

    Cancer is one of the leading causes of death in both developed and developing countries and also a major public health problem This dreadful disease is spreading with continuance and increasing incidences in recent times In million cancer patients died as per the reports of World Health Organization WHO which also estimated the increase in annual cancer cases

EDITORIAL SECTION

  • EXPERT Talk

    PHARMA LOGISTICS TRENDS

    Pharma logistics is undergoing profound change throughout Asia as the ageing population drives a growing need for new pharma solutions together with s...